Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Private Asset Management Inc. (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Nektar Therapeutics stock include Curet Myriam,
Find the latest Nektar Therapeutics (NKTR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Top institutional investors include Private Asset Management Inc. (0.02%). View Nektar Therapeutics NKTR investment & stock information. Get the latest Nektar Therapeutics NKTR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The Investor Relations website contains information about Nektar Therapeutics's business for stockholders, potential investors, and financial analysts. View the latest Nektar Therapeutics (NKTR) stock price, news, historical charts, analyst ratings and financial information from WSJ. A high-level overview of Nektar Therapeutics (NKTR) stock.
Nektar Therapeutics (NKTR) stock is trading at $19.14 as of 10:38 AM on Tuesday, Dec 22, a rise of $0.49, or 2.63% from the previous closing price of $18.65. The stock has traded between $18.67 and $19.46 so far today. Watch Nektar Therapeutics trade live. Nektar Therapeutic's stock tanked more than 40% on Friday after the biopharmaceutical company disclosed a quality-control issue with a key cancer treatment. Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California.
2021-03-26
2021-03-01 · Last month we talked about how Nektar Therapeutics stock seems to be a good buying opportunity, and now there have been more positive developments for the company. Last week, Nektar announced that 2021-03-24 · Nektar Therapeutics has a market cap of $3.83 Billion and is expected to release its quarterly earnings report on May 05, 2021- May 10, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the NKTR stock to lose ahead of the earnings release. 2021-04-09 · Real time Nektar Therapeutics (NKTR) stock price quote, stock graph, news & analysis.
Investerare har över tid godtagit stadigt lägre priser för att komma ut ur Nektar Therapeutics och aktien ligger i en fallande trendkanal på medellång sikt.
Prices shown are actual historical values and are not adjusted for either splits or dividends.
Nektar Therapeutics. USA. 50. NLSN. Nielsen N.V. Ordinary Shares.
Gekas bonus
2020-08-18 · View today's stock price, news and analysis for Nektar Therapeutics (NKTR). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Customizable interactive chart for Nektar Therapeutics with latest real-time price quote, charts, latest news, technical analysis and opinions. Nektar Therapeutics has 618 employees across 3 locations and $152.92 M in annual revenue in FY 2020. See insights on Nektar Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
The all-time high Nektar Therapeutics stock closing price was 108.44 on March 08, 2018. The Nektar Therapeutics 52-week high stock price is 26.75, which is 13.3% above the current share price. Find the latest Nektar Therapeutics (NKTR) stock discussion in Yahoo Finance's forum.
Beijer ref eqt
2020-08-19 · NKTR: Get the latest Nektar Therapeutics stock price and detailed information including NKTR news, historical charts and realtime prices.
136. 0,00. Laboratory Corporation of America.
Kurs kroner pund
2021-03-24 · Nektar Therapeutics has a market cap of $3.83 Billion and is expected to release its quarterly earnings report on May 05, 2021- May 10, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the NKTR stock to lose ahead of the earnings release.
2021-04-09 · Nektar Therapeutics stock price target cut to $16 vs. $54 at Goldman Sachs. Oct. 8, 2019 at 8:15 a.m. ET by Ciara Linnane. Nektar Therapeutics downgraded to sell vs. buy at Goldman Sachs. Get the latest Nektar Therapeutics (NKTR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Private Asset Management Inc. (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Nektar Therapeutics stock include Curet Myriam,
Tuesday, January 14, 2020. 06:28 PM ET. Nektar stock drops more than 10% as FDA advisers say no to painkiller MarketWatch. Tuesday 2020-06-05 Nektar Therapeutics (NKTR) stock is trading at $19.14 as of 10:38 AM on Tuesday, Dec 22, a rise of $0.49, or 2.63% from the previous closing price of $18.65. The stock has traded between $18.67 and $19.46 so far today. Volume today is less active than usual.
Please note that any opinions, estimates or forecasts regarding Nektar Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Nektar Therapeutics or its management. Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know. Zacks. Feb-03-20 09:12AM : US STOCKS-Wall Street set to open higher after steep selloff.